A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting

  • Jack C
  • Lalloo U
  • Karim Q
 et al. 
  • 34

    Readers

    Mendeley users who have this article in their library.
  • 58

    Citations

    Citations of this article.

Abstract

To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban TB clinic in South Africa. Patients with smear-positive pulmonary TB were offered HIV counseling and testing. Twenty HIV-positive patients received once-daily didanosine (400 mg) plus lamivudine (300 mg) plus efavirenz (600 mg) administered concomitantly with standard TB therapy Monday to Friday and self-administered on weekends. After completing TB therapy, patients were referred to an HIV clinic for continued treatment. At baseline, patients had a mean CD4 count of 230 cells/mm(3) (range: 24-499 cells/mm(3)) and a mean viral load of 5.75 log(10) (range: 3.81-7.53 log(10)). Seventeen completed combined standard TB and HIV therapy; 16 of 20 (80%) patients enrolled and 15 of 17 (88%) patients completing standard TB therapy achieved a viral load

Author-supplied keywords

  • Access to antiretroviral therapy
  • HAART
  • HIV/AIDS
  • Once-daily HAART
  • Tuberculosis directly observed therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Christopher Jack

  • Umesh Lalloo

  • Quarraisha Abdool Karim

  • Salim Abdool Karim

  • Wafaa El-Sadr

  • Sharon Cassol

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free